{
    "name": "propylthiouracil",
    "comment": "Rx",
    "other_names": [
        "PTU"
    ],
    "classes": [
        "Antithyroid Agents"
    ],
    "source": "https://reference.medscape.com/drug/ptu-propylthiouracil-342735",
    "pregnancy": {
        "common": [
            "Pregnancy Category: D",
            "Lactation: distributed in breast milk, contraindicated by some sources (AAP Committee states compatible w/ nursing ; AAFP states safe for nursing)"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: distributed in breast milk, contraindicated by some sources (AAP Committee states compatible w/ nursing ; AAFP states safe for nursing)"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Severe liver injury and acute liver failure, some of which have been fatal, have been reported in adult and pediatric patients taking propylthiouracil",
                "Closely monitor for symptoms and signs of liver injury (eg, , anorexia, nausea, vomiting, fatigue, pruritus, dark colored urine, or jaundice), especially during first 6 months after initiating therapy",
                "Reserve propylthiouracil use for those unable to tolerate other treatments (eg, methimazole, radioactive iodine, surgery)",
                "Propylthiouracil may be the treatment of choice during and just before the first trimester of pregnancy (strong association of methimazole with congenital malformation during first trimester)"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of severe rare immunoallergenic hepatitis",
                "Severe dermatologic reactions reported",
                "Discontinue in presence of unexplained fever",
                "Lupus-like syndrome reported (may need to discontinue)",
                "Glomerulonephritis and interstitial nephritis with acute renal failure reported",
                "Interstitial pneumonitis may occur",
                "High relapse rate (more likely in smokers)",
                "Agranulocytosis within first 3 months of therapy reported; instruct patients to immediately report any symptoms suggestive of agranulocytoses, such as fever or sore throat; leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur; discontinue treatment if agranulocytosis, aplastic anemia (pancytopenia) suspected, and patient's bone marrow indices obtained",
                "Patients who receive therapy should be under close surveillance and counseled regarding necessity of immediately reporting any evidence of illness, particularly sore throat, skin eruptions, fever, headache, or general malaise; in such cases, white blood cell and differential counts should be obtained to determine whether agranulocytosis has developed; particular care should be exercised with patients who are receiving concomitant drugs known to be associated with agranulocytosis",
                "Cases of vasculitis resulting in severe complications and death reported; cases of vasculitis include: glomerulonephritis, leukocytoclastic cutaneous vasculitis, alveolar/pulmonary hemorrhage, cerebral angiitis, and ischemic colitis; severe cases require treatment with corticosteroids, immunosuppressant therapy, and plasmapheresis; if vasculitis is suspected, discontinue therapy and initiate appropriate intervention",
                "Propylthiouracil can cause hypothyroidism necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state; because drug readily crosses placental membranes, propylthiouracil can cause fetal goiter and cretinism when administered to a pregnant woman"
            ],
            "specific": [
                {
                    "type": "Liver toxicity",
                    "description": [
                        "Patients should be instructed to report any symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, light-colored stools, dark urine, right upper quadrant pain, etc.), particularly in first six months of therapy; when these symptoms occur, measurement should be made of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT/AST levels)",
                        "Biochemical monitoring of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST) not expected to attenuate risk of severe liver injury due to rapid and unpredictable onset",
                        "Liver injury resulting in liver failure, liver transplantation, or death, reported with therapy in adult and pediatric patients",
                        "No cases of liver failure reported with use of methimazole in pediatric patients; therapy not recommended for pediatric patients except when methimazole not well-tolerated and surgery or radioactive iodine therapy are not appropriate therapies",
                        "Patients should be informed of risk of liver failure; patients should be instructed to report symptoms of hepatic dysfunction (anorexia, pruritus, right upper quadrant pain, etc.), particularly in first six months of therapy",
                        "When symptoms occur, therapy should be discontinued immediately and liver function tests and ALT and AST levels obtained; discontinue immediately if abnormal LFTs (transmainase>3 times ULN)"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sodium iodide I-131",
            "description": {
                "common": "propylthiouracil will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Contraindicated. Discontinue antithyroid medications at least 3-4 days before administering sodium iodide I-131 and do not coadminister; thyroid agents decrease update of sodium iodide I-131 by the thyroid gland"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "propylthiouracil, carbamazepine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of agranulocytosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "propylthiouracil, clozapine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of agranulocytosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macimorelin",
            "description": {
                "common": "propylthiouracil, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that may blunt the growth hormone (GH) response to macrimorelin may impact the accuracy of the diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methimazole",
            "description": {
                "common": "propylthiouracil, methimazole.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of agranulocytosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "propylthiouracil and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "propylthiouracil, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, propylthiouracil.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "propylthiouracil decreases effects of antithrombin alfa by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "propylthiouracil decreases effects of antithrombin III by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "argatroban",
            "description": {
                "common": "propylthiouracil decreases effects of argatroban by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bemiparin",
            "description": {
                "common": "propylthiouracil decreases effects of bemiparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "propylthiouracil decreases effects of bivalirudin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dalteparin",
            "description": {
                "common": "propylthiouracil decreases effects of dalteparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "propylthiouracil decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "propylthiouracil decreases effects of fondaparinux by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "heparin",
            "description": {
                "common": "propylthiouracil decreases effects of heparin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lycopus",
            "description": {
                "common": "lycopus increases effects of propylthiouracil by pharmacodynamic synergism. Use Caution/Monitor. Lycopus blocks peripheral conversion of T4 to T3."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenindione",
            "description": {
                "common": "propylthiouracil decreases effects of phenindione by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium iodide",
            "description": {
                "common": "potassium iodide, propylthiouracil. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Concomitant use with antithyroid drugs may potentiate the hypothyroid and goitrogenic effects of potassium iodide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protamine",
            "description": {
                "common": "propylthiouracil decreases effects of protamine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "propylthiouracil increases levels of theophylline by decreasing elimination. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "propylthiouracil decreases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cadexomer iodine",
            "description": {
                "common": "cadexomer iodine, propylthiouracil. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypothyroid effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iodinated glycerol",
            "description": {
                "common": "iodinated glycerol, propylthiouracil. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypothyroid effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iodine",
            "description": {
                "common": "iodine, propylthiouracil. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypothyroid effects."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Aplastic anemia",
            "percent": null
        },
        {
            "name": "Dermatologic reactions",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "Polyarthritis",
            "percent": null
        },
        {
            "name": "Drowsiness",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "Erythema nodosum",
            "percent": null
        },
        {
            "name": "Exfoliative dermatitis",
            "percent": null
        },
        {
            "name": "Skin rash",
            "percent": null
        },
        {
            "name": "Skin ulcers",
            "percent": null
        },
        {
            "name": "Goiter",
            "percent": null
        },
        {
            "name": "Weight gain",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Loss of taste",
            "percent": null
        },
        {
            "name": "Granulopenia",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Inhibition of myelopoiesis",
            "percent": null
        },
        {
            "name": "agranulocytosis",
            "percent": null
        },
        {
            "name": "granulopenia",
            "percent": null
        },
        {
            "name": "aplastic anemia",
            "percent": null
        },
        {
            "name": "and thrombocytopenia",
            "percent": null
        },
        {
            "name": "Drug fever",
            "percent": null
        },
        {
            "name": "a lupus",
            "percent": null
        },
        {
            "name": "like syndrome",
            "percent": null
        },
        {
            "name": "including splenomegaly and vasculitis",
            "percent": null
        },
        {
            "name": "Periarteritis",
            "percent": null
        },
        {
            "name": "Hypoprothrombinemia",
            "percent": null
        },
        {
            "name": "Bleeding",
            "percent": null
        },
        {
            "name": "Nephritis",
            "percent": null
        },
        {
            "name": "Glomerulonephritis",
            "percent": null
        },
        {
            "name": "Interstitial pneumonitis",
            "percent": null
        },
        {
            "name": "Exfoliative dermatitis",
            "percent": null
        },
        {
            "name": "Erythema nodosum",
            "percent": null
        },
        {
            "name": "Vasculitis syndrome associated with the presence of antineutrophilic cytoplasmic antibodies",
            "percent": null
        },
        {
            "name": "ANCA",
            "percent": null
        },
        {
            "name": "Skin rash",
            "percent": null
        },
        {
            "name": "Uticaria",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Epigastric distress",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Paresthesias",
            "percent": null
        },
        {
            "name": "Loss of taste",
            "percent": null
        },
        {
            "name": "Taste perversion",
            "percent": null
        }
    ]
}